Cagrilintide

Cagrilintide API

Cagrilintideyog ib tug ntev-acting, chemically synthesizedCov tshuaj amylin receptor agonist, tsim raws li kev kho tshiab raurog rog thiab hnyav-txog cov kab mob metabolic. Nws yog tsim los ua raws li cov teebmeem ntawmtib neeg amylin, ib qho tshuaj hormone co-secreted nrog insulin los ntawm pancreatic β-hlwb, uas ua lub luag haujlwm tseem ceeb hauv kev tswj cov zaub mov noj, plab hnyuv, thiab satiety.

Cagrilintide yog tsim los ua ib qhokev txhaj tshuaj ib zaug ib lub lim tiam, muab kev cog lus zoo heev rautswj qhov hnyav hnyav, tshwj xeeb tshaj yog thaum siv hauvua ke nrog GLP-1 receptor agonistsxws liSemaglutide.

Mechanism ntawm Action

Cagrilintide siv nws txoj kev kho mob los ntawm kev khi rau thiab ua kom muaj zogcov tshuaj amylin receptors, ua rau:

• Kev tshaib plab

• Ncua plab hnyuv, uas prolongs qhov kev xav ntawm fullness

• Txo cov calorie kom tsawg thiab nce satiety

Qhov kev tswj hwm ntau yam ntawm kev noj zaub mov no ua rau nws yog tus neeg sib tw zoo tshaj plaws rau kev tswj hwmrog rog thiab muaj feem cuam tshuam cardiometabolic txaus ntshai.

Kev tshawb fawb thiab cov ntaub ntawv kho mob

Cagrilintide tau pom cov txiaj ntsig tau zoo hauv ntau qhov kev sim tshuaj, suav nrogTheem 2 kev tshawb fawb ua los ntawm Novo Nordisk:

• Thaum sivib leeg, Cagrilintide ua raukoob tshuaj-nyob ntawm qhov hnyav poob, nrog rau10.8% lub cev hnyav txotshaj 26 lub lis piam hauv cov neeg rog rog.

• Thaum twgua ke nrog Semaglutide, cov nyhuv yuag yog txhim khu kev qha-ua tiavKev txo qis hauv lub cev hnyav dua li tus neeg sawv cev ib leeg.

• Nws tau qhiatxaus siab tolerabilitythiabkev ruaj ntseg profile, nrog rau feem ntau cov xwm txheej tsis zoo yog cov tsos mob me me hauv plab hnyuv.

Qhov kev sib xyaw ua ke no yog qhov tseem ceeb ntawm kev sib twtiam tom ntej los tiv thaiv kev rog rog pipeline, tsom ntau txoj hauv kev txaus siab (amylin + GLP-1).

API Quality thiab Manufacturing

PebCagrilintide API:

• Yog tsim los ntawm advancedsolid-phase peptide synthesis (SPPS)nrog siab purity thiab tshuaj stability

• yog tsim rautxhaj tshuaj formulation kev loj hlob

• Raws li thoob ntiaj tebCov qauv tshuaj (ICH, GMP, FDA)

• Muaj nyob rau hauvpilot rau kev lag luam-scale ntau lawm, haum rau kev kho mob thiab kev lag luam siv

Kev kho muaj peev xwm

Cagrilintide sawv cev rau atshiab mechanismHauv kev tswj qhov hnyav dhau GLP-1 monotherapy. Nws complementary action profile ua rau nws haum rau:

• Cov neeg rog rog rog thiab rog rog(nrog lossis tsis muaj ntshav qab zib)

• Kev sib xyaw ua kerau enhanced yuag poob

• Kev txhim kho yav tom ntej hauvmetabolic syndrome thiab prediabetes